Repositioning Candidate Details
| Candidate ID: | R0760 |
| Source ID: | DB05295 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Eldecalcitol |
| Synonyms: | 1α,25-dihydroxy-2β-(3-hydroxypropoxy)cholecalciferol; Eldecalcitol |
| Molecular Formula: | C30H50O5 |
| SMILES: | [H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O |
| Structure: |
|
| DrugBank Description: | Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation. |
| CAS Number: | 104121-92-8 |
| Molecular Weight: | 490.725 |
| DrugBank Indication: | Investigated for use/treatment in osteoporosis. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Eldecalcitol is an analog of 1a,25-dihydroxyvitamin D3 , bearing a hydroxypropoxy residue at the 2b position. Eldecalcitol is also effective in increasing bone mass and was able to enhance bone strength in rodents. It binds to the vitamin D receptor (VDR) with less affinity but binds to vitamin D-binding protein with higher affinity than 1,25(OH)2D, showing a long half-life in plasma. |
| Targets: | Vitamin D3 receptor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |